High Prevalence of hyperhomocysteinaemia among Indian patients of vascular disease.

Source: OAI
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The global burden of disease indicates that cancers and vascular disease are responsible for the maximum morbidity and mortality. Hyperhomocysteinemia has been implicated as a risk marker/factor in both. Also measures to reduce circulating concentrations of homocysteine are fairly simple and without side effects. Yet such measures are not part of the management of these conditions. This review attempts to bring forth the necessity to include homocysteine-lowering therapy in the management of several disease conditions to reduce the morbidity and mortality.
    05/2014; DOI:10.1016/j.cmrp.2014.06.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is limited data on the role of hyperhomocysteinemia as a risk factor for cerebral veno-sinus thrombosis (CVT) in Indians. We examined the association between plasma homocysteine (Hcy), methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, and CVT in 185 patients with aseptic CVT (puerperal 80 and nonpuerperal 105) and 248 healthy controls (puerperal 67 and nonpuerperal 181). Fasting Hcy was higher in patients compared to controls (20.25 ± 5.97 vs 9.81 ± 5.19 μmol/L, P < .001) and associated with 4.54-fold (95% confidence interval [CI]: 2.74-7.53) increase in risk of CVT. Risk was higher in puerperal (odds ratio [OR]: 8.7, 95% CI: 2.73-26.91) compared to nonpuerperal CVT (OR: 3.82, 95% CI: 2.09-6.96). Plasma Hcy was higher in MTHFR 677TT compared to 677CT and 677CC genotypes (34.44 ± 32.8 vs 25.81 ± 33.3 vs 18.50 ± 23.7 μmol/L, respectively, P < .001), but the risk associated with MTHFR 677TT was insignificant (OR: 1.91, 95% CI: 0.53-7.06). We conclude that hyperhomocysteinemia is a risk marker for Indian patients with aseptic CVT. MTHFR 677TT genotype is not linked with CVT but is a determinant of plasma Hcy.
    Clinical and Applied Thrombosis/Hemostasis 11/2012; 20(1). DOI:10.1177/1076029612466285 · 1.58 Impact Factor